{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T18:38:21Z","timestamp":1792780701963,"version":"4.5.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Brucellosis is a major zoonotic infection worldwide, with the highest burden reported in the Mediterranean region. The therapeutic role of fluoroquinolones in this disease continues to be controversial. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of fluoroquinolone-containing regimens compared with standard non-fluoroquinolone regimens for the treatment of human brucellosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In accordance with PRISMA recommendations, this systematic review and meta-analysis assessed the efficacy and safety of fluoroquinolone-based regimens for treating brucellosis. It was prospectively registered in PROSPERO (CRD420251142019). A comprehensive search of PubMed, Scopus, Web of Science, and the Cochrane Library was carried out, including studies published through August 2025. Randomized controlled trials comparing fluoroquinolones with conventional therapies (such as doxycycline with streptomycin or rifampicin) were included. Therapeutic failure, relapse, adverse events, and time to defervescence were the main outcomes. To compute pooled risk ratios and mean differences with 95%CIs, data were analyzed using STATA v18. The GRADE method and the RoB 2 tool were used to evaluate the risk of bias and the certainty of the evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis comprised 9 clinical studies with 602 brucellosis patients. When compared to standard regimens, fluoroquinolone-based regimens were linked to a significantly higher risk of therapeutic failure (RR\u2009=\u20092.11, 95% CI: 1.26\u20133.51; P\u2009=\u20090.004) and a higher, though not statistically significant, risk of relapse (RR\u2009=\u20091.88, 95% CI: 0.94\u20133.74; P\u2009=\u20090.07). No statistically significant between-study heterogeneity was observed for either outcome (I\u00b2\u2009=\u20090%). Subgroup analyses showed a significantly increased risk of therapeutic failure in patients with uncomplicated brucellosis and in studies with treatment durations &gt;8 weeks, although between-subgroup differences were not statistically significant. On the other hand, no statistically significant difference in adverse events was observed between fluoroquinolone-based and standard regimens under the random-effects model (RR\u2009=\u20090.62, 95% CI: 0.29\u20131.33; P\u2009=\u20090.22). Although the point estimate favored fluoroquinolone-based regimens, the confidence interval included the null effect\n                      <jats:bold>.<\/jats:bold>\n                      Fluoroquinolone-based regimens were also associated with a significantly longer time to defervescence compared with standard regimens (MD\u2009=\u20091.20 days, 95% CI: 0.66\u20131.74; P\u2009&lt;\u20090.001). The certainty of evidence was moderate for therapeutic failure, and time to defervescence, and low for relapse and adverse events according to the GRADE evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with conventional doxycycline-based combinations, fluoroquinolone-based regimens were associated with a higher risk of therapeutic failure and longer time to defervescence, while the overall risk of relapse did not differ significantly. No significant difference in adverse events was observed with the random-effects model, although the point estimate favored fluoroquinolone-based regimens. Overall, these findings do not support the routine use of fluoroquinolones as first-line therapy for adult brucellosis. Further well-designed randomized controlled trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0013822","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:44:16Z","timestamp":1792777456000},"page":"e0013822","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of fluoroquinolones in the treatment of human brucellosis: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Mohsen","family":"Mohammadi-Sartang","sequence":"first","affiliation":[{"name":"Shiraz University of Medical Sciences","place":["Shiraz, Iran"],"department":["Department of Clinical Nutrition, School of Nutrition and Food Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Rafieipour","sequence":"additional","affiliation":[{"name":"Islamic Azad University","place":["Rasht Branch, Rasht, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Afrasiabian","sequence":"additional","affiliation":[{"name":"Research Institute for Health Development, Kurdistan University of Medical Sciences","place":["Sanandaj, Iran"],"department":["Zoonoses Research Center"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Tabriz University of Medical Sciences","place":["Tabriz, Iran"],"department":["Nutrition Research Center, School of Nutrition and Food Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-5930","authenticated-orcid":true,"given":"Yousef","family":"Moradi","sequence":"additional","affiliation":[{"name":"Ume\u00e5 University","place":["Ume\u00e5, Sweden"],"department":["Department of Diagnostics and Intervention"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medi","family":"Karimi","sequence":"additional","affiliation":[{"name":"Bogomolets National Medical University","place":["Kyiv, Ukraine"],"department":["Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1037-9341","authenticated-orcid":true,"given":"Karo","family":"Servatyari","sequence":"additional","affiliation":[{"name":"Research Institute for Health Development, Kurdistan University of Medical Sciences","place":["Sanandaj, Iran"],"department":["Zoonoses Research Center"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"1","key":"pntd.0013822.ref001","doi-asserted-by":"crossref","DOI":"10.1097\/MRM.0000000000000266","article-title":"A review of brucellosis in the Middle East and control of animal brucellosis in an Iranian experience","volume":"33","author":"N Bahmani","year":"2021","journal-title":"Rev Med Microbiol"},{"issue":"5","key":"pntd.0013822.ref002","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/tmi.12856","article-title":"Human-to-human transmission of Brucella - A systematic review","volume":"22","author":"FF Tuon","year":"2017","journal-title":"Trop Med Int Health"},{"key":"pntd.0013822.ref003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0378-1135(02)00214-6","article-title":"Brucella intracellular life: From invasion to intracellular replication","volume":"90","author":"JP Gorvel","year":"2002","journal-title":"Vet Microbiol"},{"issue":"1","key":"pntd.0013822.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/vbz.2023.0063","article-title":"Prevalence of Brucella melitensis and Brucella abortus fluoroquinolones resistant isolates: A systematic review and meta-analysis","volume":"24","author":"M Beig","year":"2024","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"6","key":"pntd.0013822.ref005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.30699\/ijmm.17.6.620","article-title":"The antibiotic susceptibility of Brucella spp. isolated from human samples: A systematic review and meta-analysis","volume":"17","author":"M Darvishi","year":"2023","journal-title":"Iran J Med Microbiol"},{"issue":"2","key":"pntd.0013822.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191993","article-title":"Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials","volume":"13","author":"F Meng","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"pntd.0013822.ref007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/AAC.50.1.22-33.2006","article-title":"Quinolones for treatment of human brucellosis: Critical review of the evidence from microbiological and clinical studies","volume":"50","author":"ME Falagas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pntd.0013822.ref008","first-page":"207","article-title":"The new fluoroquinolones: A critical review","volume":"10","author":"GG Zhanel","year":"1999","journal-title":"Can J Infect Dis"},{"key":"pntd.0013822.ref009","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pntd.0013822.ref010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019"},{"issue":"9","key":"pntd.0013822.ref011","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.37.9.1831","article-title":"Quinolones in treatment of human brucellosis: Comparative trial of ofloxacin-rifampin versus doxycycline-rifampin","volume":"37","author":"M Akova","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pntd.0013822.ref012","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jclinepi.2014.01.006","article-title":"Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable","volume":"67","author":"G Gopalakrishna","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"pntd.0013822.ref013","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s100960050344","article-title":"Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis","volume":"18","author":"C Agalar","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"85","key":"pntd.0013822.ref014","article-title":"A new therapeutic management in acute uncomplicated brucellosis: Comparison between three month-ofloxacin and doxycycline-based regimens","volume":"25","author":"A Alikhani","year":"2007","journal-title":"J Isfahan Med School"},{"key":"pntd.0013822.ref015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0399-077X(96)80077-1","article-title":"Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucellosis","volume":"26","author":"T Kalo","year":"1996","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"key":"pntd.0013822.ref016","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-4-18","article-title":"Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: A randomized clinical trial [ISRCTN11871179]","volume":"4","author":"O Karabay","year":"2004","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pntd.0013822.ref017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1258\/td.2009.090030","article-title":"A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis","volume":"39","author":"F Keramat","year":"2009","journal-title":"Trop Doct"},{"issue":"6","key":"pntd.0013822.ref018","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/26.6.841","article-title":"Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis","volume":"26","author":"R Lang","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0013822.ref019","unstructured":"Didgar F. Comparison between efficacy of ciprofioxacin-doxycycline and rifampin-doxycycline regimens in treatment of brucellosis. 2012."},{"issue":"5","key":"pntd.0013822.ref020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1179\/joc.2003.15.5.466","article-title":"Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: A prospective, randomized study","volume":"15","author":"Y Bayindir","year":"2003","journal-title":"J Chemother"},{"issue":"8","key":"pntd.0013822.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012405","article-title":"Updated therapeutic options for human brucellosis: A systematic review and network meta-analysis of randomized controlled trials","volume":"18","author":"S Huang","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013822.ref022","doi-asserted-by":"crossref","first-page":"19037","DOI":"10.1038\/s41598-024-69669-w","article-title":"A systematic review and meta-analysis of comparative clinical studies on antibiotic treatment of brucellosis","volume":"14","author":"S Maduranga","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"pntd.0013822.ref023","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1186\/s12879-025-11688-7","article-title":"Research mapping and comparative assessment of drug treatment regimens for brucellosis: A systematic review and network meta-analysis","volume":"25","author":"A Pele","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"3","key":"pntd.0013822.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012010","article-title":"Efficacy and safety of therapeutic strategies for human brucellosis: A systematic review and network meta-analysis","volume":"18","author":"SN Silva","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0013822.ref025","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3390\/microorganisms10102003","article-title":"Brucella phagocytosis mediated by pathogen-host interactions and their intracellular survival","volume":"10","author":"TXN Huy","year":"2022","journal-title":"Microorganisms"},{"key":"pntd.0013822.ref026","doi-asserted-by":"crossref","first-page":"1608617","DOI":"10.3389\/fmicb.2025.1608617","article-title":"Beyond survival to domination: Brucella\u2019s multilayered strategies for evading host immune responses","volume":"16","author":"Z Wei","year":"2025","journal-title":"Front Microbiol"},{"issue":"2","key":"pntd.0013822.ref027","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.BAI-0006-2019","article-title":"The intracellular life cycle of Brucella spp","volume":"7","author":"J Celli","year":"2019","journal-title":"Microbiol Spectr"},{"key":"pntd.0013822.ref028","doi-asserted-by":"crossref","first-page":"1129172","DOI":"10.3389\/fcimb.2023.1129172","article-title":"The mechanism of chronic intracellular infection with Brucella spp","volume":"13","author":"X Guo","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"pntd.0013822.ref029","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.diagmicrobio.2007.06.017","article-title":"Uptake of ciprofloxacin and ofloxacin by 2 Brucella strains and their fluoroquinolone-resistant variants under different conditions. An in vitro study","volume":"59","author":"A Turkmani","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"pntd.0013822.ref030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0003-2670(97)00465-0","article-title":"Spectrofluorimetric study of the acid\u2013base equilibria and complexation behavior of the fluoroquinolone antibiotics ofloxacin, norfloxacin, ciprofloxacin and pefloxacin in aqueous solution","volume":"354","author":"AI Drakopoulos","year":"1997","journal-title":"Analytica Chimica Acta"},{"key":"pntd.0013822.ref031","doi-asserted-by":"crossref","first-page":"1474957","DOI":"10.3389\/fmicb.2024.1474957","article-title":"Exploring genetic determinants of antimicrobial resistance in Brucella melitensis strains of human and animal origin from India","volume":"15","author":"H Ayoub","year":"2024","journal-title":"Front Microbiol"},{"issue":"4","key":"pntd.0013822.ref032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.eimc.2014.03.010","article-title":"Emergence of quinolone-resistant, topoisomerase-mutant Brucella after treatment with fluoroquinolones in a macrophage experimental infection model","volume":"33","author":"E Rodr\u00edguez Tarazona","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"5","key":"pntd.0013822.ref033","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3855\/jidc.20643","article-title":"In-vitro antimicrobial susceptibility results of Brucella species; Single center study from Eastern T\u00fcrkiye","volume":"19","author":"M K\u0131l\u0131\u00e7 Tekin","year":"2025","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"pntd.0013822.ref034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejps.2012.04.022","article-title":"Predicting the exposure and antibacterial activity of fluoroquinolones based on physicochemical properties","volume":"47","author":"G V\u00f6lgyi","year":"2012","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"pntd.0013822.ref035","doi-asserted-by":"crossref","first-page":"2585620","DOI":"10.1080\/21505594.2025.2585620","article-title":"Pathogenicity and virulence of Brucella: Strategies for metabolic adaptation and immune evasion","volume":"16","author":"ES Guimar\u00e3es","year":"2025","journal-title":"Virulence"},{"issue":"7","key":"pntd.0013822.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010635","article-title":"Antibiotic persistence of intracellular Brucella abortus","volume":"16","author":"S Mode","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013822.ref037","author":"M Munang\u2019andu","year":"2024"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:44:23Z","timestamp":1792777463000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013822"}},"subtitle":[],"editor":[{"given":"Mohammad","family":"Jokar","sequence":"first","affiliation":[{"name":"University of Calgary","place":["CANADA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013822","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]}}}